Education
About Us
Working with TipRanks
Follow Us
Verona Pharma (VRNA)
:VRNA
VRNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.50 - $106.13
Previous CloseN/A
Volume658.49K
Average Volume (3M)1.81M
Market Cap
$9.11B
Enterprise Value$8.40B
Total Cash (Recent Filing)$438.02M
Total Debt (Recent Filing)$244.37M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Nov 11, 2025EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding86,192,120
10 Day Avg. Volume1,271,785
30 Day Avg. Volume1,812,150
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue37.91
Enterprise Value/Gross Profit39.84
Enterprise Value/Ebitda-229.61
Forecast
1Y Price Target
$106.22Price Target Upside0.11% Upside
Rating ConsensusHold
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Product Approval And GrowthOhtuvayre has established strong revenue growth, showing a fast adoption among physicians and patients.
Product DifferentiationMerck management expressed enthusiasm for Ohtuvayre's unique dual mechanism that is differentiated by being steroid-free.
Strategic AcquisitionMerck will acquire Verona Pharma to expand its portfolio in cardiopulmonary disease treatments.
Bears Say
Acquisition PremiumThe takeout premium isn't high by historical standards.
Cost ConcernsIncreased costs have been modeled, resulting in a reduction in net income for 2025.
Stock Rating DowngradeIn the wake of the deal announcement, the rating was downgraded to Neutral from the prior Buy.
Verona Pharma News
VRNA FAQ
What was Verona Pharma’s price range in the past 12 months?
Verona Pharma lowest stock price was $24.50 and its highest was $106.13 in the past 12 months.
What is Verona Pharma’s market cap?
Verona Pharma’s market cap is $9.11B.
When is Verona Pharma’s upcoming earnings report date?
Verona Pharma’s upcoming earnings report date is Nov 11, 2025 which is in 68 days.
How were Verona Pharma’s earnings last quarter?
Verona Pharma released its earnings results on Jul 31, 2025. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of $0.029 by -$0.034.
Is Verona Pharma overvalued?
According to Wall Street analysts Verona Pharma’s price is currently Undervalued.
Does Verona Pharma pay dividends?
Verona Pharma does not currently pay dividends.
What is Verona Pharma’s EPS estimate?
Verona Pharma’s EPS estimate is 0.18.
How many shares outstanding does Verona Pharma have?
Verona Pharma has 86,192,120 shares outstanding.
What happened to Verona Pharma’s price movement after its last earnings report?
Verona Pharma reported an EPS of -$0.005 in its last earnings report, missing expectations of $0.029. Following the earnings report the stock price went down -0.048%.
Which hedge fund is a major shareholder of Verona Pharma?
Currently, no hedge funds are holding shares in VRNA
Verona Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$106.22 (0.11% Upside)
$106.22 (0.11% Upside)
Blogger Sentiment
Neutral
VRNA Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 939.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
290.18%
12-Months-Change
Fundamentals
Return on Equity
-36.38%
Trailing 12-Months
Asset Growth
31.96%
Trailing 12-Months
Company Description
Verona Pharma
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
VRNA Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights significant achievements such as the strong launch of O2VERE, robust financial performance, and strategic advancements in pipeline and market expansion. However, challenges remain with operating losses and seasonality impacts. Overall, the positive developments and financial strength present an optimistic outlook for the company.View all VRNA earnings summariesVRNA Stock 12 Month Forecast
Average Price Target
$106.22
▲(0.11% Upside)
Technical Analysis
Corcept Therapeutics
―
Ascendis Pharma
―
Blueprint Medicines
―
BridgeBio Pharma
―
Roivant Sciences
―
Ownership Overview
36.45% Insiders
14.13% Mutual Funds
0.10% Other Institutional Investors
48.74% Public Companies and Individual Investors